tirzepatide peak sales Semaglutide & Tirzepatide: Leading GLP-1 Drug in 2024 Lilly's tirzepatide and Novo Nordisk's

Thats often more than older GLP-1 drugs like semaglutide achieve (A major study found ~50% of participants on tirzepatide lost ~15% of their weight)

The timing trap Many women start tirzepatide for weight loss without thinking about fertility at all

Another negative reviewer mentioned concerns about medication labeling from Trava newer pharmacy partner

The most common side effects are mild digestive ones nausea, constipation, or acid reflux especially in the first weeks as your dose adjusts

Among them, the activation of GLP-1 receptors delays gastric emptying, reduces appetite, lowers blood sugar and improves insulin sensitivity

Lingvay I, Sumithran P, Cohen RV, le Roux CW